Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP002 for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT00957918Phase 2Completed
- Sponsor
- Neuraltus Pharmaceuticals
- Start
- Oct 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing Nicotine with Placebo (2 arms). Primary endpoints: frequency and severity of adverse events and measure of impulse control (rMIDI) at 14 weeks. Started Oct 2009; status: completed.
02
Drugs
nicotine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT00957918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957918.